NCT01529203 - Subjects' Satisfaction on Pan Facial Aesthetic Enhancement After Treatment With Azzalure® and the Restylane® Range | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 29, 2012

Primary Completion Date

April 30, 2013

Study Completion Date

April 30, 2013

Conditions

Aging

Interventions

DRUG

Botulinum Toxin Type A (Azzalure)

Powder for solution for injection

DEVICE

Restylane ranges

Hyaluronic acid (HA) 20 mg/mL + Lidocaine 0.3% (Restylane® Lidocaine, Restylane® Perlane™ Lidocaine, Restylane® SubQ Lidocaine, Restylane® Lip Volume, Restylane® Lip Refresh)

Trial Locations (5)

Unknown

Galderma investigational site, Bordeaux

Galderma investigational site, Metz

Galderma investigational site, Madrid

Galderma investigational site, London

Galderma investigational site, Street